NeuroPace, Inc. reported a significant increase in financial performance for the third quarter of 2025, with revenues reaching $27.4 million, a 30% increase from $21.1 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $73.4 million, up 26% from $58.4 million in the prior year. The company attributed this growth primarily to an increase in the number of RNS System units sold, alongside higher sales of DIXI Medical products and service revenue. Despite the revenue growth, NeuroPace recorded a net loss of $3.5 million for the quarter, an improvement from a loss of $5.5 million in Q3 2024, and a net loss of $18.7 million for the nine-month period, down from $21.9 million year-over-year.
The company’s gross profit margin improved to 77.4% in Q3 2025, compared to 73.2% in Q3 2024, driven by lower fixed costs per unit due to increased production volume. Operating expenses also rose, with sales and marketing expenses increasing by 27% to $12.6 million, reflecting higher personnel costs and marketing initiatives. Research and development expenses rose by 14% to $6.6 million, while general and administrative expenses increased by 15% to $4.6 million. The total operating expenses for the quarter were $23.8 million, up from $19.7 million in the prior year.
In terms of operational developments, NeuroPace's customer base and product adoption rates have shown positive trends. The company has focused on expanding its market presence, particularly in Level 4 comprehensive epilepsy centers in the U.S. Following the expiration of its exclusive distribution agreement with DIXI Medical on September 30, 2025, NeuroPace is in a wind-down period where it can sell remaining inventory. The company is also actively pursuing collaborations, such as its agreement with Rapport Therapeutics to leverage data from its RNS System for clinical trials.
Looking ahead, NeuroPace plans to continue investing in research and development, particularly for expanding indications of its RNS System to include patients with generalized epilepsy and those under 18 years of age. The company has sufficient liquidity, with cash, cash equivalents, and short-term investments totaling $60 million as of September 30, 2025, which it believes will support operations for at least the next 12 months. However, the company acknowledges the need for additional funding to support ongoing commercialization efforts and product development, particularly in light of its accumulated deficit of $549.7 million.
About NeuroPace Inc
NeuroPace, Inc. develops and commercializes the RNS System, a brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. The system monitors brain activity, recognizes abnormal patterns, and delivers targeted electrical pulses to prevent seizures. It provides clinicians with continuous data, supports personalized therapy, and improves patient outcomes. The company serves adult epilepsy patients, primarily in the U.S., with a focus on expanding indications and markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.